Patents by Inventor Sian Rowsell

Sian Rowsell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystal structure of aurora a kinase and uses thereof
    Patent number: 7214518
    Abstract: The invention provides crystalline forms of a polypeptide corresponding to the catalytic domain of Aurora kinase. The active site ATP binding pocket is defined by its amino acid residues and their atomic coordinates. This structure may be used to select or design chemical modulators of Aurora kinase, particularly Aurora inhibitors. These modulators may be used to treat diseases of cell proliferation, e.g. cancer.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: May 8, 2007
    Assignee: AstraZeneca AB
    Inventors: Malcom Anderson, Nicholas John Keen, Andrew David Bruce Pannifer, Richard Alexander Pauptit, Sian Rowsell
  • Crystal structure of enzyme and uses thereof
    Publication number: 20060078975
    Abstract: The invention provides crystalline forms of a polypeptide corresponding to the catalytic domain of Aurora kinase. The active site ATP binding pocket is defined by its amino acid residues and their atomic coordinates. This structure may be used to select or design chemical modulators of Aurora kinase, particularly Aurora inhibitors. These modulators may be used to treat diseases of cell proliferation, e.g. cancer.
    Type: Application
    Filed: October 8, 2002
    Publication date: April 13, 2006
    Applicant: AstraZeneca AB
    Inventors: Malcom Anderson, Nicholas Keen, Andrew David Pannifer, Richard Pauptit, Sian Rowsell
  • Crystallised catalytic domain of matrix metalloproteinase 9 (mmp9) and the use of its three dimensional structure to design mmp9 modulators
    Publication number: 20040175817
    Abstract: The invention provides a crystalline form of a polypeptide corresponding to the catalytic domain of a matrix metalloproteinase protein, MMP9. The active site binding region of the MMP9 protein is defined by its amino acid residues and their atomic coordinates. This three dimensional structure may be used to select or design chemical modulators or MMP9, particularly MMP9 inhibitors. These modulators may be used to treat a metalloproteinase mediated disease or condition.
    Type: Application
    Filed: December 12, 2003
    Publication date: September 9, 2004
    Inventors: Holly Jepson, Claire Minshull, Richard Pauptit, Sian Rowsell